Zhang, Weizhou

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

Khan, S., Zhang, X., Lv, D., Zhang, Q., He, Y., Zhang, P., Liu, X., Thummuri, D., Yuan, Y., Wiegand, J. S., et al. (2019) · Nature Medicine

Protein Degradation and InhibitorsCell death mechanisms and regulation

Cited by 688

Obesity-associated NLRC4 inflammasome activation drives breast cancer progression

Kolb, R., Phan, L., Borcherding, N., Liu, Y., Yuan, F., Janowski, A. M., Xie, Q., Markan, K. R., Li, W., Potthoff, M. J., et al. (2016) · Nature Communications

Inflammasome and immune disordersImmune cells in cancer

Cited by 239

Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,

Lv, D., Pal, P., Liu, X., Jia, Y., Thummuri, D., Zhang, P., Hu, W., Pei, J., Zhang, Q., Zhou, S., et al. (2021) · Nature Communications

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 158

Obesity and breast cancer: A case of inflamed adipose tissue

Kolb, R., & Zhang, W. (2020) · Cancers

Cancer Risks and FactorsAdipokines, Inflammation, and Metabolic Diseases

Cited by 119